Drug Combination Details

General Information of the Combination (ID: C15588)
Name Celastrol   NP Info  + Trastuzumab   Drug Info 
Structure +
Disease
Breast cancer [ICD-11: 2C60]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression c-RAF  Molecule Info 
Pathway MAP
Down-regulation Expression HER2  Molecule Info 
Pathway MAP
Down-regulation Expression HSPA4  Molecule Info 
Pathway MAP
                    In-vitro Model SK-BR-3 CVCL_0033 Breast adenocarcinoma Homo sapiens
BT-474 CVCL_0179 Invasive breast carcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
BT-20 CVCL_0178 Invasive breast carcinoma Homo sapiens
MCF-10A CVCL_0598 Healthy Homo sapiens
                    In-vivo Model Four to six week old female NOD-SCID mice received sub-cutaneous 17Beta-estradiol pellet (0.72 mg/day), 2 weeks prior to injection of 5 * 106 BT-474 cells resuspended in 4% Matrigel.
                    Experimental
                    Result(s)		 Celastrol strongly synergized with ErbB2-targeted therapeutics Trastuzumab, producing higher cytotoxicity with substantially lower doses of Celastrol.
References
Reference 1 Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011 Jan 15;11(2):263-76.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link